(HealthDay News) – For patients with bladder cancer undergoing radical cystectomy, a robotic approach seems to have the same oncologic efficacy as an open approach and demonstrates potential perioperative benefits, according to a pilot study published in the February issue of The Journal of Urology.
Dipen J. Parekh, MD, from the University of Texas Health Sciences Center at San Antonio, and colleagues conducted a prospective randomized trial comparing the perioperative outcomes and oncologic efficacy of open and robotic assisted laparoscopic radical cystectomy. Data were available for 40 patients.
The researchers observed no significant differences between the groups with respect to the oncologic outcomes of positive margins (5% each) or the number of lymph nodes removed (23 for open radical cystectomy vs. 11 for robotic assisted laparoscopic radical cystectomy; P=0.135). The estimated blood loss was reduced for the robotic assisted laparoscopic radical cystectomy group (400mL) compared with the open radical cystectomy group (800mL). In addition, there was a trend toward a decreased rate of stays >5 days in the robotic group (65% vs. 90%; P=0.11) as well as a trend toward fewer transfusions (40% vs. 50%, P=0.26).
“Our results suggest no significant differences in surrogates of oncologic efficacy. Robotic assisted laparoscopic radical cystectomy demonstrates potential benefits of decreased estimated blood loss and decreased hospital stay compared to open radical cystectomy,” the authors write. “Our results need to be validated in a larger multicenter prospective randomized clinical trial.”